AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02222025 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injury Prevention Programme
Description: The injury prevention program will be included at the beginning of the usual football training by replacing the traditional warm-up. The programme will be conducted by the coaches at least two times a week (with exception of school holidays). The prevention programme contains seven exercises and lasts about 15 min after familiarisation. Three exercises focus on unilateral, dynamic stability of the lower extremities (hopping, jumping and landing). Further, three exercises emphasize whole body and trunk stability. The last exercise contains rolling movements to improve fall technique. The difficulty of each exercise can be progressively increased in five steps. Players start at the level of difficulty which corresponds to their current performance level. They will proceed to the next level when they perform the exercises with good control. This will be assessed by the coaches.
Study NCT03152006 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ACT
Description: Coordinated, graduated transition which includes an early introduction to the adult clinician during the PAPA pre-transfer period, a peer-facilitated organized support group aimed at improving transition readiness and addressing critical psychosocial skills including self-efficacy and locus of control and a case management team including a patient advocate who coordinates the transfer between pediatric and adult care teams.
Study NCT02822547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: Patients will receive Peginterferon alfa-2a according to the standard medical practice
Study NCT00704275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.05% cyclosporin eye drop
Description: bid dosage for 4 months
Study NCT00704275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.05% cyclosporin eye drop
Description: bid dosage for 4 months
Study NCT01014923 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Teen driving intervention
Description: Parents of new teen drivers receive guidebook to teach driving skills and safety behaviors; individual instruction on parent-child communication about driving; DVD demonstrating safe driving communication; and, 26-page booklet on driving goals and conversation topics
Study NCT03373227 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envarsus
Description: Patients will take once daily Envarsus
Study NCT02660840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg Flupentixol film-coated tablet (test treatment)
Description: single oral dose, fasted state, day 1 in period 1 or 2
Study NCT02660840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg Flupentixol film-coated tablet (test treatment)
Description: single oral dose, fasted state, day 1 in period 1 or 2
Study NCT02660840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Flupentixol film-coated tablet (test treatment)
Description: single oral dose, fasted state, day 1 in period 1 or 2
Study NCT02660840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.5 mg Flupentixol coated tablet (reference treatment)
Description: single oral dose, fasted state, day 1 in period 1 or 2
Study NCT02660840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1 mg Flupentixol coated tablet (reference treatment)
Description: single oral dose, fasted state, day 1 in period 1 or 2
Study NCT02660840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg Flupentixol coated tablet (reference treatment)
Description: single oral dose, fasted state, day 1 in period 1 or 2
Study NCT02539056 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chondron Implantation
Description: In one vial (0.4 ml), Main ingredient: 1.2 million or more autologous chondrocytes Culture solution: Adequate amount of Dulbecco's modified Eagle medium (DMEM) The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
Study NCT03343353 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: LED (Light Emission Diode)
Description: LED light application in cutaneous lesions from the graft donor area (scalp) in patients who are victims of burns
Study NCT03343353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LED (Light Emission Diode)
Description: LED light application in cutaneous lesions from the graft donor area (scalp) in patients who are victims of burns
Study NCT03253419 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Home for Life mobile application
Description: Utilize home application to provide the participant with an understanding and recommendations to potentially decrease home hazards that may lead to risk of falls in their home.
Study NCT00557817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alpha (Aranesp)
Description: Darbepoetin alpha (Aranesp) will be administered subcutaneously (s.c.) at the dose of 300 µg. The first dose will be given on day 28 and the following doses at 2-week intervals around days 42, 56, 70, 84, 98 and 112 post-transplant. Once the target Hb (13 g/dL) has been attained, the dose of Aranesp will be reduced by half to 150 µg. If the Hb increases to > 14 g/dL, Aranesp will be withheld and resumed at the dose of 150 µg when the Hb decreases \< 13 g/dL. If the Hb decreases to \< 12 g/dL, the dose of Aranesp will be increased to 300 µg again.
Study NCT00557817 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Iron saccharate (Venofer)
Description: Iron saccharate (Venofer) will be administered intravenously (i.v.) at the dose of 200 mg (2 vials of Venofer) on days 28, 42 and 56 after the transplant. Venofer will be diluted in 250 ml saline and infused over 60 minutes. Iron will be omitted in patients with severe iron overload (serum ferritin > 2500 µg/L in the absence of inflammation or liver necrosis) or elevated transferrin saturation (TS > 60%) between days 21 and 56. No iron supplementation will be allowed in arm 1. No iron supplementation will be allowed in arm 2 before day 70 after the transplant. In arms 2 and 3, if patients have evidence of functional iron deficiency (transferrin saturation \< 20%) on day 70 or later, they will receive 300 mg of Venofer over 90 min, for a minimum of 2 doses.
Study NCT04929717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breastfeeding education and counseling
Description: Breastfeeding education was applied for four weeks.
Study NCT04929717 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine postpartum breastfeeding training included in the hospital procedure
Description: The routine breastfeeding postpartum educational training given to all women by healthcare personnel as part of the hospital procedures.
Study NCT04929717 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine postpartum breastfeeding training included in the hospital procedure
Description: The routine breastfeeding postpartum educational training given to all women by healthcare personnel as part of the hospital procedures.
Study NCT01520428 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing, CBT and E-mail support
Description: Motivational Interviewing, elements of Cognitive Behaviour Therapy and E-mail support
Study NCT04118257 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sugary beverage: Fruit juice
Description: Participants consumed 100% fruit juice (\~710mL) daily for three weeks, along with their habitual diets.
Study NCT04118257 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sugary beverage: Soda
Description: Participants consumed soda (\~710mL) daily for three weeks, along with their habitual diets.
Study NCT04118257 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Control: Water
Description: Participants consumed water (\~710mL) daily for three weeks, along with their habitual diets.
Study NCT02532166 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Esophageal lichen planus
Description: White light endoscopy compared to narrow band imaging and Lugol for detection of esophageal lichen.
Study NCT00390026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin)
Study NCT00390026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab (Avastin)
Study NCT00390026 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verteporfin photodynamic therapy (PDT)
Study NCT00390026 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Verteporfin photodynamic therapy (PDT)
Study NCT00561977 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High Fiber Diet
Description: high fiber diet (≥30 grams of total fiber per day); reduction of calories to -500 from resting metabolic rate (RMR), not less than 1200 kcal per day.
Study NCT00561977 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: low saturated fat diet
Description: low saturated fat diet (≤7% of total calories); -500 calories from RMR, not less than 1200 kcal/day.
Study NCT00561977 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combination diet
Description: combination low saturated fat high fiber diet, with calorie restriction as specified.
Study NCT03127982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol
Description: The Unified Protocol (UP) is a trans-diagnostic cognitive-behavioral therapy (tCBT) for individuals diagnosed with anxiety disorders, depression and related disorders (which we refer to as emotional disorders).
Study NCT03127982 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Unified Protocol
Description: The Unified Protocol (UP) is a trans-diagnostic cognitive-behavioral therapy (tCBT) for individuals diagnosed with anxiety disorders, depression and related disorders (which we refer to as emotional disorders).
Study NCT02700334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: 10 mg, one per day before breakfast during 12 weeks.
Study NCT02700334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one per day before breakfast during 12 weeks.
Study NCT00654147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir & Lopinavir/ritonavir
Description: Two drug regimen of an integrase inhibitor and ritonavir boosted protease inhibitor
Study NCT00654147 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Raltegravir and emtricitabine/tenofovir
Description: Three drug regimen of an integrase inhibitor and a fixed dose combination of a non-nucleoside/nucleotide inhibitors
Study NCT02647450 — intervention group
Intervention type: OTHER
Intervention: GIANT Completed patient
Description: Patients identified in the GIANT clinic and who fulfill the inclusion criteria will be sent a 9 page questionnaire. Upon receipt the questionnaire will be sent to the patient's GP for validation.
Study NCT02660008 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZP4207
Description: Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of ZP4207 administered s.c. to hypoglycemic Type 1 diabetic patients
Study NCT02660008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GlucaGen
Description: Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of GlucaGen administered s.c. to hypoglycemic Type 1 diabetic patients
Study NCT01005121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: colchicine
Description: 2mg, per-os, once daily for six months
Study NCT03856268 — intervention group
Intervention type: PROCEDURE
Intervention: 'Surgical Menopause' Group
Description: Women undergoing laparoscopic oophorectomy surgery ('surgical menopause') will be enrolled at Pennington Biomedical.
Study NCT03856268 — intervention group
Intervention type: DRUG
Intervention: 'Drug-Induced Menopause' Group
Description: Women undergoing gonadal suppression via leuprolide acetate (Lupron \[AbbVie Inc.\]) will be enrolled at the University of Colorado-Denver.
Study NCT03460743 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Study group - quadrivalent recombinant hemagglutinin influenza vaccine
Description: Eligible subjects will be randomized, 1:1, to receive one or two doses of same vaccine. Subjects will be categorized in two age groups: subjects 9 to 17 years will be allocated in Group A and will receive one dose; Subjects 3 to 8 will be allocated to group B and the ACIP/CDC algorithm will be applied to determine should one or two doses will be applied 28 days apart. Vaccinator will be non blind and will not participate in the clinical evaluation.
Study NCT03460743 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Control group - quadrivalent inactivated influenza vaccine
Description: Eligible subjects will be randomized, 1:1, to receive one or two doses of same vaccine. Subjects will be categorized in two age groups: subjects 9 to 17 years will be allocated in Group A and will receive one dose; Subjects 3 to 8 will be allocated to group B and the ACIP/CDC algorithm will be applied to determine should one or two doses will be applied 28 days apart. Vaccinator will be non blind and will not participate in the clinical evaluation.
Study NCT00816023 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ecallantide
Description: infusion administered IV over the duration of the surgical procedure
Study NCT00816023 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: solution for IV infusion over the duration of the surgical>> procedure
Study NCT03473080 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Internet CBT
Description: The treatment consists of a standard cognitive behavior therapy for OCD with additional treatment components to make the treatment better suited for children and adolescents with Autism Spectrum Disorder.
Study NCT01054183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlideScope Ranger Intubation
Description: Intubation with GlideScope Ranger Video Laryngoscope
Study NCT01054183 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Direct Laryngoscopy
Description: Intubations will be done with direct laryngoscopy.
Study NCT02619539 — intervention group
Intervention type: PROCEDURE
Intervention: plasma fibrinogen measurement
Description: plasma fibrinogen measurement
Study NCT02181517 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abicipar pegol
Description: Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.
Study NCT02181517 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ranibizumab
Description: Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
Study NCT02181517 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sham procedure
Description: Sham procedure to the study eye at weeks 12 and 16.
Study NCT01967498 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast
Study NCT01251640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY86-9766+Gemcitabine
Description: Phase I: 40 mg/day (20 mg twice daily), 60 mg/day (30 mg twice daily, 100 mg/day (50 mg bid) dependent on safety/tolerability Phase II: Recommended Phase II dose (RP2D) dependent on the results of the Phase I part of this study Route of administration: Oral, twice daily (bid) in combination with gemcitabine 1000 mg/m2 Intravenous infusion over 30 minutes weekly for seven out of eight weeks (Cycle 1); followed by 1000 mg/m2 Intravenous infusion over 30 minutes weekly for three out of four weeks (Cycle 2 and subsequent)
Study NCT02811276 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: The High-Protein Diet Group will receive a eucaloric diet composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based meal replacement (Almased®) for one and a half day. Participants will consume 1 gram ± 0.1 of Almased® per kg of body weight mixed with linseed oil and skim milk in their breakfast, lunch and dinner. Two snacks (afternoon and evening) composed of 1 gram ± 0.1 of Almased® per kg of body weight mixed with vegetable juice and linseed oil will also be provided.
Study NCT02536183 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance high intensity focused ultrasound
Description: Magnetic resonance (MR)-high intensity focused ultrasound (HIFU) provides precise controlled delivery of heat by focusing ultrasound energy inside a lesion using an external applicator that is completely non-invasive and non-ionizing.
Study NCT02536183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyso-thermosensitive liposomal doxorubicin
Description: A heat-activated formulation of liposomal doxorubicin with unique property of heat-activated release of doxorubicin, an active agent in most pediatric solid tumors.
Study NCT04921813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3 dimensional scoliosis exercise
Description: Schroth exercises
Study NCT04921813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance Exercise
Description: Balance-coordination exercises
Study NCT04921813 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brace treatment
Description: Brace usage
Study NCT01090583 — intervention group
Intervention type: OTHER
Intervention: Specimen Collection
Description: We will compare mediators from non-invasive samples (blood, urine, saliva, vaginal or cervical secretions) with traditional gold-standard invasive samples (amniotic fluid and placenta samples).
Study NCT03037645 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SNS-062
Description: SNS-062 will be orally administered twice daily and available in capsules containing either 25 mg or 100 mg of active ingredient.
Study NCT01239732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 175 mg/m\^2 on Day 1 every 3 weeks or at a dose of 80 mg/m\^2 every week for a minimum of 4 cycles and not more than 8 cycles or until disease progression or unacceptable toxicity, whichever occurs first
Study NCT01239732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg intravenously on Day 1 of every cycle for up to 36 cycles of 3 weeks each or until disease progression or unacceptable toxicity, whichever occurs first
Study NCT01239732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: AUC 5-6 mg/ml/min on Day 1 every 3 weeks for a minimum of 4 cycles and not more than 8 cycles or until disease progression or unacceptable toxicity, whichever occurs first
Study NCT04049019 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Urine collection
Description: The child will collect:~* Urine at bedtime.~* First morning voided volume
Study NCT00237133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letrozole
Description: 1 tablet of Letrozole 2.5 mg orally adminnistered once a day
Study NCT00732940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab 100 mg SC
Description: Belimumab 100 mg SC for 1 injection on Days 0, 7, 14, and then every two weeks.
Study NCT00732940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belimumab 100 mg SC
Description: Belimumab 100mg SC for 2 injections (of 100mg each) on Days 0, 2, and 4, then 100 mg (1 injection) three times per week.
Study NCT01950637 — intervention group
Intervention type: BEHAVIORAL
Intervention: survey
Description: Completion of 58-item online questionnarie.
Study NCT00321646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab (marketed as Avastin, Genentech) is an antibody to all isoforms of vascular endothelial growth factor and is the first putative anti-angiogenic agent approved by the Food and Drug Administration (FDA) for the treatment of cancer.All subjects will be treated with intravenous docetaxel and bevacizumab for 5 cycles, followed by docetaxel alone for Cycle 6. Bevacizumab will be given first, at a starting dose of 15 mg/kg. Bevacizumab will be given once every 21 days in the infusion center.
Study NCT00321646 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be given intravenously once every 21 days in the infusion center. The starting dose is 70mg/square meter.
Study NCT01598142 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Team 1
Description: experienced endoscopist with a experienced assistant
Study NCT01598142 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Team 2
Description: same experienced endoscopist with a new trained assistant
Study NCT04036123 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urodynamic investigation
Description: Simultaneous UDI (same session repeat filling cystometry and pressure flow study) with an air-charged and water-perfused measurement system.
Study NCT01621815 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Video Game
Description: Playing various video games: RPG, Race, FPS, Strategy
Study NCT02772757 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard hearing aid fitting
Description: standard hearing aid, face-to-face fitting
Study NCT02772757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: coupler-based fitting
Description: coupler-based fitting using average RECDs
Study NCT03982862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: Triamcinolone 4mg diluted to 0.1 ml
Study NCT03982862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone
Description: Triamcinolone 4mg diluted to 0.1 ml
Study NCT03982862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 0.1ml 2% Xylocaine